Three-year clinical outcome of patients with bifurcation treatment with second-generation Resolute and Xience V stents in the randomized TWENTE trial

Lam, Ming Kai; Sen, Hanim; Houwelingen, K. Gert van; Löwik, Marije M.; Heijden, Liefke C. van der; Kok, Marlies M.; Man, Frits H.A.F. de; Linssen, Gerard C.M.; Tandjung, Kenneth; Doggen, Carine J.M.; Birgelen, Clemens von

doi:10.1016/j.ahj.2014.10.011

Cited by 19 publications

(15 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there was some imbalance in clinical presentation in the bifurcation subgroup (more NSTEMI in SES; more unstable angina in BES) which may have obscured some of the periprocedural MI in the SES group in patients presenting with NSTEMI with biomarkers already elevating pre‐procedural. A recent report from the TWENTE trial also showed higher periprocedural MI rates in bifurcation lesions when using EES and ZES newest generation DES . It is noteworthy that at 5‐year follow‐up, there was no longer a statistical significant difference in MI between BES and SES due to a late “catch‐up” in MI events related to the higher incidence of very late ST in Cypher.…”

Section: Discussionmentioning

confidence: 95%

First generation versus second generation drug‐eluting stents for the treatment of bifurcations: 5‐year follow‐up of the LEADERS all‐comers randomized trial

Grundeken

Wykrzykowska

Ishibashi

et al. 2015

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 95%

First generation versus second generation drug‐eluting stents for the treatment of bifurcations: 5‐year follow‐up of the LEADERS all‐comers randomized trial

Grundeken

Wykrzykowska

Ishibashi

et al. 2015

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

“…These findings were confirmed by a retrospective study in 319 patients, who were treated with Xience for TBL, showing favorable angiographic and 1-year clinical outcomes in patients treated with a 2-stent technique [30]. Despite the overall favorable outcome of bifurcation treatment with second-generation DES, there has been a higher incidence of periprocedural MI [13, 14, 27]. …”

Section: Discussionmentioning

confidence: 87%

“…The comparison of findings from different bifurcation stent studies is hampered by the fact that there is no uniformity in the minimum size of (relevant) side-branches and no general consent on whether to determine side-branch size visually or per QCA [4, 10, 13, 14, 25, 40]. Bifurcation lesions with side-branches ≥2 mm, as addressed in our present study, were also examined in the Z-SEAside and the SEAside studies [9, 25].…”

Section: Discussionmentioning

confidence: 99%

“…This might be related to the increased procedural complexity of bifurcation stenting or the atherosclerotic disease itself, which both are generally higher in patients with TBL. Only few large randomized clinical trials have reported data on the long-term performance of second-generation DES in bifurcated target lesions [13, 14, 16]. However, these studies comprised target lesions with a variety of bifurcation types, and clinical outcome was generally reported at the group level without specifying outcome for patients with TBL versus non-TBL [13, 14].…”

Section: Introductionmentioning

confidence: 99%

“…Only few large randomized clinical trials have reported data on the long-term performance of second-generation DES in bifurcated target lesions [13, 14, 16]. However, these studies comprised target lesions with a variety of bifurcation types, and clinical outcome was generally reported at the group level without specifying outcome for patients with TBL versus non-TBL [13, 14]. As a consequence, long-term outcome data of patients who were treated with second-generation DES in TBL are of interest but scarce [17].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Long-term outcome and chest pain in patients with true versus non-true bifurcation lesions treated with second-generation drug-eluting stents in the TWENTE trial

et al. 2016

Self Cite

View full text Add to dashboard Cite

The objective of this study is to assess 3-year clinical outcome of patients with true bifurcation lesions (TBLs) versus non-true bifurcation lesions (non-TBLs) following treatment with second-generation drug-eluting stents (DES). TBLs are characterized by the obstruction of both main vessel and side-branch. Limited data are available on long-term clinical outcome following TBL treatment with newer-generation DES. We performed an explorative sub-study of the randomized TWENTE trial among 287 patients who had bifurcated target lesions with side-branches ≥2.0 mm. Patients were categorized into TBL (Medina classes: 1.1.1; 1.0.1; 0.1.1) versus non-TBL to compare long-term clinical outcome. A total of 116 (40.4 %) patients had TBL, while 171 (59.6 %) had non-TBL only. Target-lesion revascularization rates were similar (3.5 vs. 3.5 %; p = 1.0), and definite-or-probable stent thrombosis rates were low (both <1.0 %). The target-vessel myocardial infarction (MI) rate was 11.3 versus 5.3 % (p = 0.06), mostly driven by (periprocedural) MI ≤48 h from PCI. All-cause mortality and cardiac death rates were 8.7 versus 3.5 % (p = 0.06) and 3.5 versus 1.2 % (p = 0.22), respectively. The 3-year major adverse cardiac event rate for patients with TBL versus non-TBL was 20.0 versus 11.7 % (p = 0.05). At 1-, 2-, and 3-year follow-up, 6.5, 13.0, and 11.0 % of patients reported chest pain at less than or equal moderate physical effort, respectively, without any between-group difference. Patients treated with second-generation DES for TBL had somewhat higher adverse event rates than patients with non-TBL, but dissimilarities did not reach statistical significance. Up to 3-year follow-up, the vast majority of patients of both groups remained free from chest pain.

show abstract

The first clinical experience with a novel directional coronary atherectomy catheter: Preliminary Japanese multicenter experience

Habara

Tsuchikane

Nasu

et al. 2016

Cathet Cardio Intervent

View full text Add to dashboard Cite

PCI with a novel DCA catheter for bifurcation lesions may be safe and effective. The clinical significance of these findings needs to be determined in future studies. This study was performed to evaluate the safety and efficacy of a novel directional coronary atherectomy catheter for bifurcation lesions. Both the device and procedural success rates were 100%. Complex stenting could be avoided in all cases. No inhospital major adverse cardiac event was observed. The novel directional coronary atherectomy catheter may be safe and effective for bifurcation lesions, even in this drug eluting stent era. © 2016 Wiley Periodicals, Inc.

show abstract

Three-year clinical outcome of patients with bifurcation treatment with second-generation Resolute and Xience V stents in the randomized TWENTE trial

Cited by 19 publications

References 32 publications

First generation versus second generation drug‐eluting stents for the treatment of bifurcations: 5‐year follow‐up of the LEADERS all‐comers randomized trial

First generation versus second generation drug‐eluting stents for the treatment of bifurcations: 5‐year follow‐up of the LEADERS all‐comers randomized trial

Long-term outcome and chest pain in patients with true versus non-true bifurcation lesions treated with second-generation drug-eluting stents in the TWENTE trial

The first clinical experience with a novel directional coronary atherectomy catheter: Preliminary Japanese multicenter experience

Contact Info

Product

Resources

About